Welcome to our dedicated page for Delek Us Hldgs SEC filings (Ticker: DK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking refinery utilization or RIN liabilities across Delek US Holdings' disclosures can mean sifting through 300-page documents. If you've ever typed "What does Delek US Holdings report in their SEC filings?" or hunted for "Delek US Holdings quarterly earnings report 10-Q filing," you know the challenge. Stock Titan resolves it with AI-powered summaries that translate dense accounting notes into plain language, highlighting crack spread sensitivity, asphalt margins, and pipeline dropdowns.
Every time a director buys shares, our platform flags "Delek US Holdings insider trading Form 4 transactions" and pushes "Delek US Holdings Form 4 insider transactions real-time" alerts to your dashboard. Need the big picture? The "Delek US Holdings annual report 10-K simplified" view connects refinery throughput data to segment EBITDA, while interactive charts turn "Delek US Holdings earnings report filing analysis" into a five-minute read. Our expert analysis answers natural questions like "understanding Delek US Holdings SEC documents with AI" without jargon.
For governance deep dives, see the "Delek US Holdings proxy statement executive compensation" section to compare pay against crack spread benchmarks, and use the "Delek US Holdings 8-K material events explained" feed to gauge how unplanned outages or MLP drop-downs move the market. From debt covenant details to hedging strategies, every disclosure updates in real time from EDGAR, giving professionals the clarity and speed they need.
Delek US Holdings (DK)17,000 shares of common stock at a weighted average price of $41.42 and 10,000 shares at a weighted average price of $41.25. Following these sales, the reporting person beneficially owns 23,020 shares, held directly.
The filing notes the trades were executed under a Rule 10b5-1 trading plan adopted on March 6, 2025 and amended August 13, 2025. Price ranges were disclosed: $41.39–$41.59 for the first set and $41.16–$41.37 for the second.
Delek US Holdings (DK) reported insider activity by EVP Joseph Israel. On 11/11/2025, he sold 20,028 shares of common stock at a weighted average price of $41.115 (range: $40.935–$41.26). The same day, 2,652 shares were withheld for taxes upon equity award vesting at $41.70. On 11/12/2025, he sold an additional 4,380 shares at a weighted average price of $40.942 (range: $40.60–$41.11).
Following these transactions, Israel directly beneficially owned 55,761 shares.
Delek US Holdings (DK): EVP insider sale reported. An executive vice president sold 5,643 shares of common stock on 11/11/2025 at a weighted average price of $41.462, with trades ranging from $41.45 to $41.51, leaving 41,269 shares directly owned after this transaction. On 11/12/2025, the EVP sold an additional 2,303 shares at a weighted average price of $40.427, with trades ranging from $40.37 to $40.48, resulting in 38,966 shares directly owned afterward.
Delek US Holdings (DK) reported an insider transaction on a Form 4. Director Ezra Uzi Yemin sold common stock on 11/07/2025 pursuant to a Rule 10b5-1 plan. Two sales were reported at a weighted average price of $43.09, reflecting multiple trades between $43.00 and $43.39 per share.
Following these transactions, beneficial ownership stands at 154,719.047 shares direct and 679,656 shares indirect held by Yemin Investments, LP.
Delek US Holdings (DK) filed a Form 144 indicating a proposed sale of 28,494 common shares. The filing lists an approximate sale date of 11/11/2025, an aggregate market value of $1,166,605.81, and identifies Merrill Lynch as broker, with trading on the NYSE.
The shares were acquired through the vesting of stock awards on multiple dates between 12/09/2023 and 11/11/2025, as shown in the acquisition table. This notice outlines an intention to sell under Rule 144 and includes the required representation regarding knowledge of material nonpublic information.
Goldman Sachs Group and Goldman Sachs & Co. LLC filed a Schedule 13G on Delek US Holdings (DK), reporting beneficial ownership of 3,171,695.56 shares, or 5.3% of the common stock, as of 09/30/2025. The filing lists shared voting power over 3,171,276.56 shares and shared dispositive power over 3,171,427.56 shares, with no sole voting or dispositive power.
The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Delek US Holdings. The 13G indicates a passive ownership position consistent with routine institutional reporting thresholds.
DK filed a Rule 144 notice for a proposed sale of common stock. The filing lists 2,303 shares to be sold on the NYSE through Fidelity Brokerage Services, with an aggregate market value of $93,103.66 and 60,051,553 shares outstanding. The approximate sale date is 11/12/2025.
The shares were acquired via the company’s Employee Stock Purchase Plan: 948 shares on 03/28/2024 (cash) and 1,355 shares on 03/31/2025 (cash). The notice includes the standard representation regarding the absence of undisclosed material adverse information.
DK filed a Form 144 notice for the proposed sale of 5,643 shares of Common Stock. The filing lists an aggregate market value of $233,972.32, with an approximate sale date of 11/11/2025. The shares are to be sold through Citigroup Global Markets Inc. on the NYSE. Shares outstanding are reported as 60,051,553.
The securities to be sold were acquired on 06/09/2025 as compensation from the issuer, in the same amount of 5,643 shares. The filing also notes a prior transaction in the last three months: Robert Wright sold 7,135 shares of Common Stock on 09/02/2025 for $208,659.51.
Delek US (DK)17,000 shares of common stock. The filing lists an aggregate market value of $703,970, with sales through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 11/11/2025.
The shares to be sold were acquired via restricted stock vesting on multiple dates, including 06/12/2022 (330), 03/10/2023 (2,141), 09/10/2024 (3,119), 06/10/2025 (1,487), and 09/10/2025 (4,482). The filing lists 60,051,553 shares outstanding.
Form 144 notice of proposed sale: A holder filed to sell 10,000 shares of common stock under Rule 144. The filing lists an aggregate market value of $414,100 and identifies Fidelity Brokerage Services LLC as broker, with sales on the NYSE and an approximate sale date of 11/11/2025. The shares were acquired through restricted stock vesting on multiple dates between 09/12/2022 and 06/10/2024.
Shares outstanding were 60,051,553 as of the filing; this is a baseline figure, not the amount being sold.
FAQ
What is the current stock price of Delek Us Hldgs (DK)?
What is the market cap of Delek Us Hldgs (DK)?
